Celgene's most recent trend suggests a bearish bias. One trading opportunity on Celgene is a Bear Call Spread using a strike $90.00 short call and a strike $100.00 long call offers a potential 14.81% return on risk over the next 29 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $90.00 by expiration. The full premium credit of $1.29 would be kept by the premium seller. The risk of $8.71 would be incurred if the stock rose above the $100.00 long call strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Celgene is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Celgene is bearish.
The RSI indicator is at 34.86 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Celgene
Better Buy: Celgene Corp. vs. Biogen
Mon, 17 Sep 2018 14:09:00 +0000
These top biotechs have entirely different philosophies when it comes to pipeline development.
Top 3 Healthcare Stocks for 2018
Mon, 17 Sep 2018 00:24:00 +0000
The healthcare industry is watching the Trump presidency closely. President Trump's promise to repeal and replace Obamacare hit repeated stumbling blocks in Congress. Despite the uncertainty surrounding these efforts to overhaul the nation's healthcare system, a number of healthcare stocks rose dramatically throughout 2017.
See what the IHS Markit Score report has to say about Celgene Corp.
Sat, 15 Sep 2018 12:06:14 +0000
Celgene Corp NASDAQ/NGS:CELG
Why bluebird and Celgene Should Worry About Amgen's Latest Clinical Victory
Fri, 14 Sep 2018 14:15:00 +0000
Cellular cancer therapies are a tough sell that could get a lot tougher.
The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion
Fri, 14 Sep 2018 13:09:01 +0000
The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion
Related Posts
Also on Market Tamer…
Follow Us on Facebook